公开(公告)号：US11224611B2

公开(公告)日：2022-01-18

申请号：US17076677

申请日：2020-10-21

Applicant: IDERA PHARMACEUTICALS, INC.

Inventor： Sudhir Agrawal ,  Daqing Wang ,  Wayne Jiang

IPC: A61K31/713 ,  A61K45/06 ,  A61P35/04 ,  A61P35/00 ,  A61K39/395 ,  C07K16/28 ,  A61K9/00

Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.

公开(公告)号：US10772907B2

公开(公告)日：2020-09-15

申请号：US16557630

申请日：2019-08-30

Applicant: IDERA PHARMACEUTICALS, INC.

Inventor： Sudhir Agrawal ,  Daqing Wang ,  Wayne Jiang

IPC: C07H21/04 ,  A61K31/713 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K45/06 ,  A61P35/04 ,  A61K9/00

Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.

公开(公告)号：US20180125877A1

公开(公告)日：2018-05-10

申请号：US15705631

申请日：2017-09-15

Applicant: IDERA PHARMACEUTICALS, INC.

Inventor： Sudhir AGRAWAL ,  Daqing JIANG ,  Wayne JIANG

IPC: A61K31/713 ,  A61P35/00 ,  A61P35/04 ,  C07K16/28 ,  A61K9/00 ,  A61K39/395

Abstract: The present invention relates to methods for treating a tumor, including a metastatic tumor, with TLR9 agonist in combination with an immune checkpoint inhibitor therapy.

公开(公告)号：US20180044669A1

公开(公告)日：2018-02-15

申请号：US15794643

申请日：2017-10-26

Applicant: IDERA PHARMACEUTICALS, INC.

Inventor： Sudhir AGRAWAL ,  Wayne JIANG ,  Daqing Wang ,  Jessica Seitzer ,  Fu-Gang Zhu ,  Xianzhi Mao

IPC: C12N15/11 ,  A61K31/7105 ,  C12N15/113 ,  A61K45/06

CPC classification number: C12N15/11 ,  A61K31/7105 ,  A61K45/06 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/314 ,  C12N2310/51

Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating PD1, PDL1, IDO1, LAG3, TIM3, CTLA4, IDO2, CEACAM1, OX40, and/or OX40L mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5′-ends to allow the presence of two or more accessible 3′-ends.

公开(公告)号：US20170233741A1

公开(公告)日：2017-08-17

申请号：US15366509

申请日：2016-12-01

Applicant: Idera Pharmaceuticals, Inc.

Inventor： Ekambar R. Kandimalla ,  Daqing Wang ,  Ireneusz Nowak ,  Sudhir Agrawal

IPC: C12N15/117 ,  A61K45/06 ,  A61K31/7125

CPC classification number: C12N15/117 ,  A61K31/7115 ,  A61K31/7125 ,  A61K45/06 ,  C12N2310/17 ,  C12N2310/31 ,  C12N2310/317 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/336 ,  C12N2310/51 ,  C12N2310/52 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/414 ,  A61K2300/00

Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

公开(公告)号：US20170009230A1

公开(公告)日：2017-01-12

申请号：US15204114

申请日：2016-07-07

Applicant: Idera Pharmaceuticals, Inc.

Inventor： Sudhir Agrawal ,  Lakshmi Bhagat ,  Fu-Gang Zhu

IPC: C12N15/113 ,  A61K45/06 ,  A61K31/713

CPC classification number: C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/3183 ,  C12N2310/51 ,  C12N2320/31 ,  A61K2300/00

Abstract: The present invention is directed to compounds, compositions, and methods useful for modulating DUX4 mRNA or protein expression using gene silencing compounds comprising two or more single stranded antisense oligonucleotides that are linked through their 5′-ends to allow the presence of two or more accessible 3′-ends.

Abstract translation: 本发明涉及使用包含两个或更多个单链反义寡核苷酸的基因沉默化合物调节DUX4mRNA或蛋白质表达的化合物，组合物和方法，所述单链反义寡核苷酸通过它们的5'-末端连接以允许存在两个或多个可接近的 3'末端。

公开(公告)号：US20150044196A1

公开(公告)日：2015-02-12

申请号：US14495523

申请日：2014-09-24

Applicant: IDERA PHARMACEUTICALS, INC.

Inventor： Sudhir Agrawal ,  Ekambar Kandimalla ,  Mallikarjuna Putta ,  Tao Lan ,  Ireneusz Nowak ,  Nicola LaMonica ,  Weiwen Jiang ,  Michael Reardon

IPC: C12N15/113 ,  A61K45/06 ,  A61K31/713

CPC classification number: C12N15/113 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/712 ,  A61K31/713 ,  A61K38/02 ,  A61K39/00 ,  A61K39/35 ,  A61K39/395 ,  A61K45/06 ,  C12N15/111 ,  C12N15/1138 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/317 ,  C12N2310/318 ,  C12N2310/344 ,  C12N2310/50 ,  C12N2310/51 ,  C12N2310/52 ,  C12N2320/30

Abstract: The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.

Abstract translation: 本发明人已经研究了提供更有效的miRNA阻断化合物的方法。 本发明人已经发现了惊人地改善miRNA阻断分子的功效的新结构特征。 这些特征包括多个3'末端的存在和在5'端的接头。 令人惊讶的是，这些特征以降低化合物生物学不稳定性的方式提高了基因表达阻断化合物的功效。 更令人惊奇的是，这种效应已被发现适用于基于DNA和RNA的寡核苷酸类化合物，并且应用于传统的反义和RNAi技术。

公开(公告)号：US20210340544A1

公开(公告)日：2021-11-04

申请号：US17286209

申请日：2019-10-18

Applicant: IDERA PHARMACEUTICALS, INC.

Inventor： Cara HAYMAKER ,  Chantale BERNATCHEZ ,  Adi DIAB ,  Srinivas CHUNDURU

IPC: C12N15/117 ,  A61K45/06 ,  C07K16/28

Abstract: The present disclosure relates to methods for treating cancer in patients having low expression of MHC Class I genes, and in patients having increased serum levels of PD-L2 by administration of a TLR9 agonist.

公开(公告)号：US09540651B2

公开(公告)日：2017-01-10

申请号：US14791749

申请日：2015-07-06

Applicant: Idera Pharmaceuticals, Inc.

Inventor： Ekambar R. Kandimalla ,  Daqing Wang ,  Ireneusz Nowak ,  Sudhir Agrawal

IPC: A61K31/7115 ,  C12N15/117 ,  A61K45/06

CPC classification number: C12N15/117 ,  A61K31/7115 ,  A61K31/7125 ,  A61K45/06 ,  C12N2310/17 ,  C12N2310/31 ,  C12N2310/317 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/336 ,  C12N2310/51 ,  C12N2310/52 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/414 ,  A61K2300/00

Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.

Abstract translation: 本发明提供作为TLR拮抗剂的新型免疫调节寡核苷酸（IRO）及其使用方法。 这些IRO具有独特的序列，其响应于TLR配体或TLR激动剂抑制或抑制TLR介导的信号传导。 该方法可用于预防和治疗癌症，自身免疫性疾病，气道炎症，炎症性疾病，感染性疾病，皮肤病，变态反应，哮喘或由病原体引起的疾病。

公开(公告)号：US20160215287A1

公开(公告)日：2016-07-28

申请号：US14791749

申请日：2015-07-06

Applicant: Idera Pharmaceuticals, Inc.

Inventor： Ekambar R. Kandimalla ,  Daqing Wang ,  Ireneusz Nowak ,  Sudhir Agrawal

IPC: C12N15/117 ,  A61K45/06 ,  A61K31/7115

CPC classification number: C12N15/117 ,  A61K31/7115 ,  A61K31/7125 ,  A61K45/06 ,  C12N2310/17 ,  C12N2310/31 ,  C12N2310/317 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/336 ,  C12N2310/51 ,  C12N2310/52 ,  Y02A50/401 ,  Y02A50/411 ,  Y02A50/414 ,  A61K2300/00

Abstract: The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.